01 / 顶尖技术
跻身世界最佳 — 为您的病例而备
韩国拥有众多跻身全球排名的医院,并在决定疑难病例的关键术式上拥有世界领先的团队。对患者而言,重要的是真正触手可及的卓越医疗。
全球最佳医院前250名的医院数 — 按国家2
韩国位居全球第三 — 以16家医院跻身Newsweek 2026前250名,仅次于美国(41)和德国(22),领先于日本(15)及所有其他受评国家。
跻身世界最佳医院1
全球最佳医院2026 — 全球排名。
- #26Samsung Medical Center · Seoul
- #28Asan Medical Center · Seoul
- #39Severance Hospital · Yonsei · Seoul
- #41Seoul National University Hospital · Seoul
- #54Seoul National University Bundang Hospital · Seongnam
- #77Gangnam Severance Hospital · Seoul
- #94Ajou University Hospital · Suwon
- #108Seoul St. Mary's Hospital · Catholic Univ. · Seoul
- #122Inha University Hospital · Incheon
- #155Korea University Anam Hospital · Seoul
- #164Kangbuk Samsung Hospital · Seoul
- #184Kyung Hee University Hospital · Seoul
- #185Konkuk University Medical Center · Seoul
- #215Chung-Ang University Hospital · Seoul
- #224Ewha Womans University Seoul Hospital · Seoul
- #227Yeouido St. Mary's Hospital · Catholic Univ. · Seoul
6,000例
全球最大活体肝移植项目(峨山)— 五年生存率85.9%。6
10,000例
单机构最大机器人甲状腺手术系列(延世);机器人手术研究全球第一。7
五年第一
三星全球第15、连续五年韩国第一智慧医院 — AI、机器人、数字影像。4
这些排名如何评定
World's Best Hospitals · Top 250
全球最佳医院(前250):依据医院质量指标(40%)、医疗专家推荐(35%)、患者体验(18.5%)和PROMs实施(6.5%)评分。共评估32个国家2,530家医院。
rankings.newsweek.com ↗World's Best Smart Hospitals · Top 350
全球最佳智慧医院(前350):依据专家声誉(77.5%)、数字化成熟度调查(20%)和JCI认证(2.5%)评分——衡量AI、机器人、远程医疗、数字影像与电子病历。
rankings.newsweek.com ↗02 / 直接就诊
直接看专科 — 无需层层转诊
在多数国家,你须先看全科医生,再等待数周乃至数月获得转诊。在韩国,你直接面见专科医生,且费用几乎无差别。
直接
无转诊门槛
在诊所和综合医院直接预约专科 — 无需全科医生转诊。
来源与参考
- [1]Newsweek & Statista, World's Best Hospitals 2026. South Korea: 7 hospitals in the global Top 100, 16 in the Top 250 — Samsung Medical Center #26, Asan Medical Center #28, Severance (Yonsei) #39, Seoul National University Hospital #41, SNU Bundang #54, Gangnam Severance #77, Ajou University Hospital #94. rankings.newsweek.com ↗
- [2]Newsweek & Statista, World's Best Hospitals 2026 — Global Top 250, counted by country across all 250 ranks. USA 41, Germany 22, South Korea 16 (3rd of 32 nations), France 15, Japan 15, Italy 13, Spain 12, UK 11, Canada 10, Switzerland 8, Netherlands 8, Australia / Brazil / Austria 7 each, Sweden / Norway 5, Israel / Belgium / India / Colombia 4. Per-capita chart uses World Bank 2024 population and excludes nations under 20 million people. rankings.newsweek.com ↗
- [3]World Bank, Total Population 2024 (SP.POP.TOTL). Used to normalize top-hospital counts per 10 million people. Korea 51.75M; USA 340.11M; Germany 83.52M; Japan 123.98M; France 68.55M; Italy 58.95M. data.worldbank.org ↗
- [4]Newsweek & Statista, World's Best Smart Hospitals 2026. South Korea: 17 hospitals among the global Top 350, 6 in the Top 100 — Samsung Medical Center ranked #15 globally (No.1 in Korea for a 5th consecutive year). rankings.newsweek.com ↗
- [5]Allemani C. et al., CONCORD-3, The Lancet (2018). Stomach-cancer 5-year age-standardized net survival: Korea ~69% — the highest in the world. Korea also leads in colon (72%) and rectal (71%) cancer survival. pmc.ncbi.nlm.nih.gov ↗
- [6]Yoon Y-I. et al., Updates in Surgery (2024); Asan Medical Center. World's highest-volume living-donor liver transplant program — 6,000 LDLT cases analyzed; adult survival 1-yr 92.7%, 5-yr 85.9%. pubmed.ncbi.nlm.nih.gov ↗
- [7]Kim H. et al., Scientific Reports (2024); Severance / Yonsei. 10,000 robotic transaxillary thyroid surgeries (2007–2023) — largest reported single-institution series. nature.com ↗
- [8]NHS England, Referral to Treatment (RTT) Waiting Times (2025–26). A GP referral is required to see an NHS specialist; ~7.2M incomplete pathways, with 61.5% seen within the 18-week standard. england.nhs.uk ↗
- [9]Fraser Institute, "Waiting Your Turn: Wait Times for Health Care in Canada, 2024." Median wait from GP referral to treatment: 30.0 weeks — the longest on record. (Fraser Institute is a free-market policy think tank.) fraserinstitute.org ↗
- [10]National Health Insurance Service (NHIS), Korea — Insurance Benefits. Outpatient coinsurance: clinic 30%, hospital 40%, general hospital 50%, tertiary 60%. A standard clinic specialist visit costs the patient ~₩4,000–6,000 (~US$3–5). nhis.or.kr ↗
- [11]HIRA / OECD Health at a Glance (2023). Koreans average ~18 outpatient visits per year — the highest in the OECD and roughly 3× the OECD average (~6.5). hira.or.kr ↗
- [12]KHIDI, 2024. Over 1.17 million international patients visited Korea in 2024 — a record high; international patient centers commonly deliver consultation, diagnostics and a treatment plan within 24–48 hours. khidi.or.kr ↗
- [13]US allogeneic stem-cell transplant cost — peer-reviewed (Transplant Cell Ther, 2023). Estimated lifetime medical cost of an allogeneic HCT patient in the ~$942k–$1.25M range. Compared with Korean international-patient estimates of ~$55k–$170k, this implies roughly an 85% saving. pmc.ncbi.nlm.nih.gov ↗
- [14]Bookimed, Bone-Marrow Transplantation in the Republic of Korea (2026). International-patient estimates: overall ~$55k–$118k; related-donor $75k–$105k; per-clinic quotes up to ~$168k. Indicative figures, not guaranteed quotes. bookimed.com ↗
- [15]MediGence / Bookimed (2026). Stage II gastric cancer (gastrectomy + stay + adjuvant chemo) — Korea ~$7k–$20k; Singapore ~$20k–$50k; Thailand ~$10k–$27k. International-patient estimates. medigence.com ↗
- [16]Peer-reviewed gastric-cancer cost data (US & multicenter China). US comprehensive gastric-cancer management commonly $50k–$150k+; multicenter China data: Stage II direct cost ~$9,004. pubmed.ncbi.nlm.nih.gov ↗
- [17]MDPI Cancers (2023), "Treatment Costs and Social Burden of Pancreatic Cancer." Pancreatic cancer (Whipple + chemotherapy): US Whipple resection median ~$57,893 plus chemotherapy ~$42k–$116k ⇒ ~$100k–$170k+; Singapore ~$37k–$85k. The Korea figure is a flagged estimate — no published Korean self-pay total was available. pmc.ncbi.nlm.nih.gov ↗
- [18]Patients Beyond Borders / KHIDI. Major procedures in Korea are commonly estimated at ~30–70% below US prices; indicative estimates that vary by procedure and provider. patientsbeyondborders.com ↗
数据说明:医院排名引自Newsweek/Statista(全球最佳医院2025–26、全球最佳智慧医院2026);国家排名为各国跻身2026全球前250名的医院数量。生存率数据来自CONCORD-3(The Lancet,2018)。可及性与等待时间数据来自NHS、Fraser Institute、NHIS与HIRA。治疗费用比较结合了同行评审的卫生经济学研究(美国)与医疗旅游/国际患者估计(Bookimed、MediGence等,针对亚洲国家);这些为参考区间而非保证报价,因患者、手术与机构而异。韩国胰腺癌数字在缺乏公开总额时为明确估计值。仅供参考;正式使用前请对照原始出处核实最新数值。
© 2026 — 大韩民国 · 医疗优势